Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study

Diagnostic Microbiology and Infectious Disease

Volumn 37, Issue 3, 2000, Pages 203-211

  Jones, Mark E ^a   Staples, Angela M ^b   Critchley, Ian ^b   Thornsberry, Clyde ^b   Heinze, Paul ^b   Engler, Howard D ^b   Sahm, Daniel F ^b  

^a MRL Pharmaceutical Services   (Netherlands)

^b 13665 Technology Drive ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFUROXIME; ERYTHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTICENTER STUDY; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; EUROPE; FLUOROQUINOLONES; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; QUINOLINES; STREPTOCOCCUS PNEUMONIAE;

EID: 0033931752     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(00)00128-0     Document Type: Article

References (32)

1. Appelbaum P.C. World-wide development of antibiotic resistance in pneumococci. Eur J Clin Microbiol. 6:1987;367-377.
2. Baquero F. Trends in antibiotic resistance of respiratory pathogens an analysis and commentary on a collaborative surveillance study . J Antimicrob Chemother. 38(suppl A:1996;117-132.
3. Baron, E. J. & Murray, P. R. (1995). Bacteriology. In P. R. Murray, E. J. Baron, M. A. Pfaller, F.C. Tenover, & R. H. Yolken, editors. Manual of clinical microbiology. (pp. 246 - 662.)Washington, D.C.: ASM Press.
4. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. N Engl J Med. 333:1995;1619-1624.
5. Biedenbach, D. J., Jones, R. N., Dipersio, J., Kugler, K. C., & Wilke, W. (1999). Fluoroquinolone resistance in H. influenzae and M. catarrhalis: frequency of occurrence and strain characteristics in the SENTRY Antimicrobial Surveillance Program 1997-1998; North America. Abstracts of the 39th ICAAC, ASM. p.141, No. 54.
6. Blaser J., Stone B.B., Groner M.C., Zinner S.H. Comparative study of enoxicin and netilmicin in a pharmacodynamic model to determine the importance of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob Agents Chemother. 31:1987;1054-1060.
7. Brueggemann, A. B., Kugler, K. C., & Doern, G. V. (1997). In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 41:1594-1597.
8. Brenwald N.P., Gill M.H., Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of streptococcus pneumoniae. Antimicrob Agents Chemother. 42:1998;2032-2035.
9. Buxbaum, A., Straschil, U., Moser, C., Graninger, W., & Georgopoulos, A. (1999). Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian bacterial surveillance network. J Antimicrob Chemother, 43(Suppl B), 13-18.
10. Chen, D. K., McGeer, A., de Azavedo J. C., & Low, D.E. (1999). Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network N Engl J Med, 341, 233-239.
11. Dalhoff, A., Petersen, U., & Endermann, E. (1996). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42:410-425.
12. Doern G.V., Brueggeman A., Holley H.P., Rauch A.M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994-1995 results of a 30 center national surveillance study . Antimicrob Agents Chemother. 40:1996;1208-1213.
13. Drusano G.L. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 32:1988;289-297.
14. Drusano G.L., Johnson D.E., Rosen M., Standiford H.C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 37:1993;483-490.
15. Felmingham D., Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens -findings of the Alexander project 1992-1996. J Chemother. 11:(Suppl 1):1999;5-21.
16. Fluit A.C., Schmitz F.J., Jones M.E., Acar J., Gupta R., Verhoef J. Antimicrobial resistance among community-acquired pneumonia isolates in Europe First results from the SENTRY Antimicrobial Surveillance Program 1997 . Int J Infect Dis. 3:1999;153-156.
17. Jones M.E., Sahm D.F., Martin N., Scheuring S., Heisig P., Thornsberry C., Köhrer K., Schmitz F.J. Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother. 44:2000;462-466.
18. Klugman K. Pneumococcal resistance to antibiotics. Clin Microbiol Rev. 3:1990;171-196.
19. National Committee for Clinical Laboratory Standards (1998). Performance standards for antimicrobial susceptibility testing; eighth informational supplement. Approved standard, document M100-S8. Villanova, PA: NCCLS.
20. Nix D.E., Sands M.F., Peloquin C.A., Vari A.J., Cumbo T.J., Vance J.W., Fracasso J.E., Schentag J.J. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract pneumonia. Am J Med. 82:1987;352-356.
21. Pestova E., Beyer R., Cianciotto N.P., Noskin G.A., Peterson L.R. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob Agents Chemother. 43:1999;2000-2004.
22. Reinert R.R., Schlaeger J.J., Lütticken R. Moxifloxacin a comparison with other antimicrobial agents of in vitro activity against Streptococcus pneumoniae . J Antimicrob Chemother. 42:1998;803-806.
23. Richard, M. P., Aguado, A., Mattina, R., Marre, R., & the SPAR study group (1998). Sensitivity to sparfloxacin and other antibiotics of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis strains isolated from adults with community acquired lower respiratory tract infections: a European multi centre study. J Antimicrob Chemother, 41, 207-214.
24. Sahm, D. F., Jones, M. E., Hickey, M. L., Diakun, D. R., Mani, S., & Thornsberry, C. (2000). Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J Antimicrob Chemother, 45, 457-466.
25. Schito, G. C., Manelli, S., Pesce, A., & the Alexander Project (1997). Trends in the activity of macrolide and β-lactam antibiotics and resistance development. J Chemother, 9(Supp.3). 18-28.
26. Schmitz F.J., Fluit A.C., Luckefahr M., Engler B., Hofmann B., Verhoef J., Heinz H.P., Hadding U., Jones M.E. The effect or reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 42:1998;807-810.
27. Souli, M., Wennersten, C. B., & Eliopoulos, G. M. (1998). In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int J Antimicrob Agents 10:23-30.
28. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis criteria for bacterial strain typing . J Clin Microbiol. 33:1995;2233-2239.
29. Thornsberry, C., Ogilvie, P., Kahn, J., Mauriz, Y., & the Laboratory Investigator Group (1997). Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis, 29, 249-257.
30. Thornsberry C., Jones M.E., Hickey M., Mauriz Y., Kahn J., Sahm D.F. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States, 1997-1998. J Antimcrob Chemother. 44:1999;749-759.
31. Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Inv. 17:1999;365-387.
32. Woodcock, J. M., Andrews, J. M., Boswell, F.J., Brenwald, N.P., & Wise, R. (1997). In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 41:101-106.